Zymeworks Inc. reports results for the quarter ended June 30 - Earnings Summary

Zymeworks

06/08/2026 22:50

Zymeworks Inc. ZYME.OQ reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 3 cents.  The mean expectation of twelve analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -71 cents to 3 cents per share.
Revenue fell 90.6% to $4.59 million from a year ago; analysts expected $16.01 million. 
Zymeworks Inc.'s reported EPS for the quarter was a loss of 62 cents​.
The company reported a quarterly loss of $45.02 million.
Zymeworks Inc. shares had fallen by 10.1% this quarter and lost 10.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 29.6% in the last three months.​ 
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Zymeworks Inc. is $37.00, about 36.5% above its last closing price of $23.50
This summary was machine generated from LSEG data August 6 at 09:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.49
-0.62
Missed
Mar. 31 2026 
-0.19
-0.59
Missed
Dec. 31 2025 
-0.42
-0.55
Missed
Sep. 30 2025 
-0.32
-0.26
Beat